![](https://cdn.sanity.io/images/0vv8moc6/onclive/380ae0e0ec7b1d7f595fac01ad4ec417b00fd4f9-1200x1200.png?fit=crop&auto=format)
First-Line Sugemalimab Plus Chemo Wins European Approval for Metastatic NSCLC
The European Commission has approved sugemalimab (Cejemly) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) that does not harbor sensitizing EGFR mutations, or …